Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

R&D Reprioritization Eliminates Most Gene Therapy Programs

 
• By Mandy Jackson
  
Sarepta laid off 500 people but promoted others in the C-suite, giving the execs raises (Shutterstock)

More from Strategy

More from Business